- AstraZeneca Plc AZN shared positive topline data from the CAPItello-291 Phase 3 trial of capivasertib in combination with Faslodex (fulvestrant) in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer patients, following recurrence or progression on or after endocrine therapy.
- The capivasertib + Faslodex combo demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus Faslodex.
- The trial will continue to assess overall survival as a key secondary endpoint.
- Related: AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study.
- The safety profile of capivasertib plus Faslodex was similar to that observed in previous trials evaluating this combination.
- AstraZeneca also reported topline data from the SERENA-2 Phase 2 trial of camizestrant.
- The trial met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.
- Tuesday, AstraZeneca reported a Phase 3 trial of Fasenra (benralizumab) that did not meet one of the two dual-primary endpoints in Eosinophilic esophagitis patients aged 12 years or older.
- Price Action: AZN shares are up 2.95% at $57.55 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
